426 related articles for article (PubMed ID: 25366680)
1. Randomized phase III trial to test accelerated versus standard fractionation in combination with concurrent cisplatin for head and neck carcinomas in the Radiation Therapy Oncology Group 0129 trial: long-term report of efficacy and toxicity.
Nguyen-Tan PF; Zhang Q; Ang KK; Weber RS; Rosenthal DI; Soulieres D; Kim H; Silverman C; Raben A; Galloway TJ; Fortin A; Gore E; Westra WH; Chung CH; Jordan RC; Gillison ML; List M; Le QT
J Clin Oncol; 2014 Dec; 32(34):3858-66. PubMed ID: 25366680
[TBL] [Abstract][Full Text] [Related]
2. Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522.
Ang KK; Zhang Q; Rosenthal DI; Nguyen-Tan PF; Sherman EJ; Weber RS; Galvin JM; Bonner JA; Harris J; El-Naggar AK; Gillison ML; Jordan RC; Konski AA; Thorstad WL; Trotti A; Beitler JJ; Garden AS; Spanos WJ; Yom SS; Axelrod RS
J Clin Oncol; 2014 Sep; 32(27):2940-50. PubMed ID: 25154822
[TBL] [Abstract][Full Text] [Related]
3. Concomitant boost radiation plus concurrent cisplatin for advanced head and neck carcinomas: radiation therapy oncology group phase II trial 99-14.
Ang KK; Harris J; Garden AS; Trotti A; Jones CU; Carrascosa L; Cheng JD; Spencer SS; Forastiere A; Weber RS
J Clin Oncol; 2005 May; 23(13):3008-15. PubMed ID: 15860857
[TBL] [Abstract][Full Text] [Related]
4. Quality of Life and Performance Status From a Substudy Conducted Within a Prospective Phase 3 Randomized Trial of Concurrent Accelerated Radiation Plus Cisplatin With or Without Cetuximab for Locally Advanced Head and Neck Carcinoma: NRG Oncology Radiation Therapy Oncology Group 0522.
Truong MT; Zhang Q; Rosenthal DI; List M; Axelrod R; Sherman E; Weber R; Nguyen-Tân PF; El-Naggar A; Konski A; Galvin J; Schwartz D; Trotti A; Silverman C; Singh A; Godette K; Bonner JA; Jones CU; Garden AS; Shenouda G; Matthiesen C; Le QT; Bruner D
Int J Radiat Oncol Biol Phys; 2017 Mar; 97(4):687-699. PubMed ID: 27727066
[TBL] [Abstract][Full Text] [Related]
5. Once-a-Week Versus Once-Every-3-Weeks Cisplatin Chemoradiation for Locally Advanced Head and Neck Cancer: A Phase III Randomized Noninferiority Trial.
Noronha V; Joshi A; Patil VM; Agarwal J; Ghosh-Laskar S; Budrukkar A; Murthy V; Gupta T; D'Cruz AK; Banavali S; Pai PS; Chaturvedi P; Chaukar D; Pande N; Chandrasekharan A; Talreja V; Vallathol DH; Mathrudev V; Manjrekar A; Maske K; Bhelekar AS; Nawale K; Kannan S; Gota V; Bhattacharjee A; Kane S; Juvekar SL; Prabhash K
J Clin Oncol; 2018 Apr; 36(11):1064-1072. PubMed ID: 29220295
[TBL] [Abstract][Full Text] [Related]
6. Final results of local-regional control and late toxicity of RTOG 9003: a randomized trial of altered fractionation radiation for locally advanced head and neck cancer.
Beitler JJ; Zhang Q; Fu KK; Trotti A; Spencer SA; Jones CU; Garden AS; Shenouda G; Harris J; Ang KK
Int J Radiat Oncol Biol Phys; 2014 May; 89(1):13-20. PubMed ID: 24613816
[TBL] [Abstract][Full Text] [Related]
7. Randomized phase I/II trial of two variants of accelerated fractionated radiotherapy regimens for advanced head and neck cancer: results of RTOG 88-09.
Fu KK; Clery M; Ang KK; Byhardt RW; Maor MH; Beitler JJ
Int J Radiat Oncol Biol Phys; 1995 Jun; 32(3):589-97. PubMed ID: 7790243
[TBL] [Abstract][Full Text] [Related]
8. A comparative study of concomitant boost radiation versus concomitant boost with concurrent chemoradiation versus standard fractionation chemoradiation in locally advanced head-and-neck cancer.
Gupta P; Dhull AK; Kaushal V
J Cancer Res Ther; 2020; 16(3):478-484. PubMed ID: 32719254
[TBL] [Abstract][Full Text] [Related]
9. Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial.
Gillison ML; Trotti AM; Harris J; Eisbruch A; Harari PM; Adelstein DJ; Jordan RCK; Zhao W; Sturgis EM; Burtness B; Ridge JA; Ringash J; Galvin J; Yao M; Koyfman SA; Blakaj DM; Razaq MA; Colevas AD; Beitler JJ; Jones CU; Dunlap NE; Seaward SA; Spencer S; Galloway TJ; Phan J; Dignam JJ; Le QT
Lancet; 2019 Jan; 393(10166):40-50. PubMed ID: 30449625
[TBL] [Abstract][Full Text] [Related]
10. Phase II/III Randomized Controlled Trial of Concomitant Hyperfractionated Radiotherapy plus Cetuximab (Anti-EGFR Antibody) or Chemotherapy in Locally Advanced Head and Neck Cancer.
Al-Saleh K; El-Sherify M; Safwat R; Elbasmy A; Shete J; Hussein A; Nazeeh M; Bedair A
Gulf J Oncolog; 2019 May; 1(30):6-12. PubMed ID: 31242976
[TBL] [Abstract][Full Text] [Related]
11. Locally advanced head and neck cancer treated with accelerated radiotherapy, the hypoxic modifier nimorazole and weekly cisplatin. Results from the DAHANCA 18 phase II study.
Bentzen J; Toustrup K; Eriksen JG; Primdahl H; Andersen LJ; Overgaard J
Acta Oncol; 2015 Jul; 54(7):1001-7. PubMed ID: 25629651
[TBL] [Abstract][Full Text] [Related]
12. Quality of Life and Performance Status From a Substudy Conducted Within a Prospective Phase 3 Randomized Trial of Concurrent Standard Radiation Versus Accelerated Radiation Plus Cisplatin for Locally Advanced Head and Neck Carcinoma: NRG Oncology RTOG 0129.
Xiao C; Zhang Q; Nguyen-Tân PF; List M; Weber RS; Ang KK; Rosenthal D; Filion EJ; Kim H; Silverman C; Raben A; Galloway T; Fortin A; Gore E; Winquist E; Jones CU; Robinson W; Raben D; Le QT; Bruner D
Int J Radiat Oncol Biol Phys; 2017 Mar; 97(4):667-677. PubMed ID: 27727063
[TBL] [Abstract][Full Text] [Related]
13. Long-term results of concomitant boost radiation plus concurrent cisplatin for advanced head and neck carcinomas: a phase II trial of the radiation therapy oncology group (RTOG 99-14).
Garden AS; Harris J; Trotti A; Jones CU; Carrascosa L; Cheng JD; Spencer SS; Forastiere A; Weber RS; Ang KK
Int J Radiat Oncol Biol Phys; 2008 Aug; 71(5):1351-5. PubMed ID: 18640496
[TBL] [Abstract][Full Text] [Related]
14. Institutional clinical trial accrual volume and survival of patients with head and neck cancer.
Wuthrick EJ; Zhang Q; Machtay M; Rosenthal DI; Nguyen-Tan PF; Fortin A; Silverman CL; Raben A; Kim HE; Horwitz EM; Read NE; Harris J; Wu Q; Le QT; Gillison ML
J Clin Oncol; 2015 Jan; 33(2):156-64. PubMed ID: 25488965
[TBL] [Abstract][Full Text] [Related]
15. Phase III randomized trial of preoperative concurrent chemoradiotherapy versus preoperative radiotherapy for patients with locally advanced head and neck squamous cell carcinoma.
Yi J; Huang X; Xu Z; Liu S; Wang X; He X; Luo D; Luo J; Xiao J; Zhang S; Wang K; Qu Y; Tang Y; Liu W; Xu G; Gao L; Wang D
Oncotarget; 2017 Jul; 8(27):44842-44850. PubMed ID: 28179586
[TBL] [Abstract][Full Text] [Related]
16. DAHANCA 28: A phase I/II feasibility study of hyperfractionated, accelerated radiotherapy with concomitant cisplatin and nimorazole (HART-CN) for patients with locally advanced, HPV/p16-negative squamous cell carcinoma of the oropharynx, hypopharynx, larynx and oral cavity.
Saksø M; Jensen K; Andersen M; Hansen CR; Eriksen JG; Overgaard J
Radiother Oncol; 2020 Jul; 148():65-72. PubMed ID: 32335364
[TBL] [Abstract][Full Text] [Related]
17. Competing causes of death in patients with locoregionally advanced head and neck cancer treated with concomitant boost radiation plus concurrent weekly cisplatin.
Gómez-Millán J; Toledo MD; Lupiañez Y; Rueda A; Trigo JM; Sachetti A; Medina JA
Clin Transl Oncol; 2013 Apr; 15(4):321-6. PubMed ID: 22911552
[TBL] [Abstract][Full Text] [Related]
18. Concurrent chemo-irradiation using accelerated concomitant boost radiation therapy in loco-regionally advanced head and neck squamous cell carcinomas.
Vivek RS; Baludavid M; Mohanram R; ; ; ; ; ;
J Cancer Res Ther; 2006; 2(3):90-6. PubMed ID: 17998685
[TBL] [Abstract][Full Text] [Related]
19. Quality of life and swallowing with standard chemoradiotherapy versus accelerated radiotherapy and panitumumab in locoregionally advanced carcinoma of the head and neck: A phase III randomised trial from the Canadian Cancer Trials Group (HN.6).
Ringash J; Waldron JN; Siu LL; Martino R; Winquist E; Wright JR; Nabid A; Hay JH; Hammond A; Sultanem K; Hotte S; Leong C; El-Gayed AA; Naz F; Ramchandar K; Owen TE; Montenegro A; O'Sullivan B; Chen BE; Parulekar WR
Eur J Cancer; 2017 Feb; 72():192-199. PubMed ID: 28040660
[TBL] [Abstract][Full Text] [Related]
20. Treatment outcomes and late toxicities of 869 patients with nasopharyngeal carcinoma treated with definitive intensity modulated radiation therapy: new insight into the value of total dose of cisplatin and radiation boost.
Ou X; Zhou X; Shi Q; Xing X; Yang Y; Xu T; Shen C; Wang X; He X; Kong L; Ying H; Hu C
Oncotarget; 2015 Nov; 6(35):38381-97. PubMed ID: 26485757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]